HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term outcomes of biliary atresia with splenic malformation.

AbstractBACKGROUND:
We assessed the long-term outcomes of patients with biliary atresia with splenic malformation (BASM).
METHODS:
We retrospectively assessed outcomes of 255 patients who underwent the Kasai procedure (KP) at our hospital between 1972 and 2014. Clinical outcomes of 11 patients with BASM (group A: nine with polysplenia, two with asplenia) and 244 patients with isolated BA (group B) were compared.
RESULTS:
The incidence of early cholangitis and hepatopulmonary syndrome (HPS) was significantly higher in group A than in group B. Of the 11 group A patients, three died of severe cardiac defects during early infancy. Seven became jaundice free following KP, with three patients subsequently requiring liver transplantation (LTx). Four survived with their native livers for 2, 5, 22, and 23years, respectively. Overall 20-year survival rates were 63.6% and 66.5% and 20-year native liver survival rates were 29.0% and 47.3% in groups A and B, respectively. No significant difference in cumulative survival rates was observed between both groups.
CONCLUSIONS:
Long-term outcomes in BASM patients without lethal cardiac defects were comparable to patients with isolated BA. Careful follow-up may be required in patients with BASM because of a potentially higher risk of secondary complications such as HPS.
AuthorsMasaki Nio, Motoshi Wada, Hideyuki Sasaki, Hiromu Tanaka, Tomohiko Watanabe
JournalJournal of pediatric surgery (J Pediatr Surg) Vol. 50 Issue 12 Pg. 2124-7 (Dec 2015) ISSN: 1531-5037 [Electronic] United States
PMID26613836 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Topics
  • Biliary Atresia (complications, surgery)
  • Cholangitis (etiology)
  • Female
  • Hepatopulmonary Syndrome (etiology)
  • Humans
  • Infant
  • Jaundice (etiology)
  • Liver Transplantation
  • Male
  • Postoperative Complications
  • Retrospective Studies
  • Spleen (abnormalities, surgery)
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: